RepliCel Life Sciences ROCE
¿Qué es el ROCE de RepliCel Life Sciences?
El ROCE de RepliCel Life Sciences, Inc. es 0.00%
¿Cuál es la definición de ROCE?
El retorno sobre el capital empleado (ROCE) es una relación financiera que mide la rentabilidad de una empresa y la eficiencia con la que se utiliza su capital.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE de compañías en Sector Health Care en TSXV en comparadas con RepliCel Life Sciences
¿Qué hace RepliCel Life Sciences?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Empresas con roce similar a RepliCel Life Sciences
- Omega Alpha Spac tiene ROCE de -0.01%
- The Gap tiene ROCE de -0.01%
- Elemental Royalties Ltd tiene ROCE de -0.01%
- Auburn National Bancorp tiene ROCE de -0.01%
- Galaxy Digital tiene ROCE de -0.01%
- The Gap tiene ROCE de -0.01%
- RepliCel Life Sciences tiene ROCE de 0.00%
- Tejon Ranch Co tiene ROCE de 0.01%
- Glen Burnie Bancorp tiene ROCE de 0.02%
- MSP Steel & Power tiene ROCE de 0.02%
- TTL Beteiligungs- und Grundbesitz-AG tiene ROCE de 0.03%
- First Foundation Inc tiene ROCE de 0.03%
- FirstMark Horizon Acquisition tiene ROCE de 0.03%